Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed

• Maximum drug concentration in plasma (Cmax) of nifedipine and candesartan [ Time Frame: within 48 hours after each dosing ] [ Designated as safety issue: No ]
• Area under the drug-concentration vs. time curve from time 0 to the last data point (AUC(0 tn)) of nifedipine and candesartan [ Time Frame: within 48 hours after each dosing ] [ Designated as safety issue: No ]

• Area under the curve (AUC) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• Dose normalized Cmax (Cmax,norm) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• AUC normalized for dose and body weight (AUCnorm) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• Area under the plasma concentration-time curve from time zero to 48h (AUC(0-48))of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• The time of the maximum concentration (Tmax) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• Half life (t1/2) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• The mean residence time (MRT) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]
• Oral plasma clearances (CL/F) of Nifedipine and Candesartan [ Time Frame: Within 48 hours after each dosing ] [ Designated as safety issue: No ]

Randomized, open label, single dose, 2-way crossover study to investigate the bioequivalence of a new fixed dose combination (FDC) tablet of nifedipine GITS and candesartan with the corresponding loose combination under fed conditions.

• Drug: Nifedipine/Candesartan, BAY98-7106
  Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
• Drug: Nifedipine (Adalat, BAYA1040) and Candesartan(Atacand,BAY12-9333)
  Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .

• Experimental: Arm 1
  Intervention: Drug: Nifedipine/Candesartan, BAY98-7106
• Active Comparator: Arm 2
  Intervention: Drug: Nifedipine (Adalat, BAYA1040) and Candesartan(Atacand,BAY12-9333)

Inclusion Criteria:

• The informed consent form must be signed before any study specific tests or procedures are done
• Confirmation of the subject's health insurance coverage prior to the first screening visit
• Healthy male subject
• Ethnicity: Caucasian
• Age: 18 to 45 years (inclusive) at the first screening visit
• Body mass index (BMI) above or equal 18, and below or equal 29.9 kg / m²
• Ability to understand and follow study-related instructions

Exclusion Criteria:

• Suspicion of drug or alcohol abuse
• Regular daily consumption of more than 1 L of xanthin-containing beverages
• Intake of foods or beverages containing grapefruit within 2 weeks prior to the first study drug administration (the same applies to pomelos and St. John's Wort)

• Use of medication within 4 weeks prior to the first study drug administration which could interfere with the investigational products (e.g. CYP3A inhibitors or CYP3A inducers)

  • examples for CYP3A inhibitors: erythromycin, inhibitors of human HIV protease (e.g. ritonavir, saquinavir), amiodarone, diltiazem, verapamil, fluconazole, itraconazole, ketoconazole, clarithromycin, telithromycin, nefazodon, cimetidine;
  • examples for CYP3A inducers: rifampicin, carbamazepin, phenytoin, phenobarbital, or products containing St. John's Wort;
• Systolic blood pressure below 116 or above 145 mmHg (after at least 15 min supine)

• At the first screening visit

  • Diastolic blood pressure above 95 mmHg (after at least 15 min supine)
  • Heart rate below 45 or above 95 beats / min (after at least 15 min supine) at the first screening visit
  • Clinically relevant findings in the physical examination
  • Positive urine drug screening or alcohol breath test
• Exclusion periods from other studies or simultaneous participation in other clinical studies